Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight

      DelveInsight Logo

      News provided by

      DelveInsight Business Research, LLP

      Nov 19, 2025, 17:31 ET

      Share this article

      Share this article


      The outlook for the KLKB1 inhibitors market is increasingly positive, driven by growing recognition of the kallikrein–kinin pathway's pivotal role in inflammatory, cardiovascular, and rare disease mechanisms. Recent product approvals, such as TAKHZYRO, EKTERLY, KALBITOR, ORLADEYO, and DAWNZTERA, along with emerging therapies such as Lonvoguran ziclumeran (Intellia Therapeutics), Navenibart (Astria Therapeutics), RZ402 (Rezolute), and others, underscore both the scientific validation and accelerating commercial potential of this therapeutic area.

      LAS VEGAS, Nov. 19, 2025 /PRNewswire/ -- DelveInsight's KLKB1 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Hereditary Angioedema, Diabetic Macular Edema, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging KLKB1 inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

      Key Takeaways from the KLKB1 Inhibitors Market Report

      • The total market size of KLKB1 inhibitors in the leading markets is expected to surge significantly by 2034.
      • The report provides the total potential number of patients in the indications, such as Hereditary Angioedema, Diabetic Macular Edema, and others.
      • Leading KLKB1 inhibitor companies, such as Intellia Therapeutics, Astria Therapeutics, Rezolute, and others, are developing novel KLKB1 inhibitors that can be available in the KLKB1 inhibitors market in the coming years. 
      • Some of the key KLKB1 inhibitors in clinical trials include Lonvoguran ziclumeran, Navenibart (STAR-0215), RZ402, and others.

      Discover which indication is expected to grab the major KLKB1 inhibitors market share @ KLKB1 Inhibitors Market Report

      Key Factors Driving the KLKB1 Inhibitors Market 

      Rising Prevalence of Hereditary Angioedema

      The increasing number of patients diagnosed with HAE, a rare genetic disorder that causes severe swelling attacks, is a primary driver. KLKB1 inhibitors target plasma kallikrein, a key enzyme in HAE pathology, providing effective treatment options for the prevention and management of attacks.

      Growing Demand for Targeted and Personalized Medicine

      KLKB1 inhibitors represent precision therapies that specifically target disease pathways, aligning with the trend toward personalized medicine in rare diseases and inflammatory conditions, which increases their appeal.

      Advancements in Drug Development

      Ongoing research and development focus on creating novel KLKB1 inhibitors such as Lonvoguran ziclumeran (Intellia Therapeutics), Navenibart (Astria Therapeutics), RZ402 (Rezolute), and others with improved efficacy, safety profiles, oral administration options, and combination therapies. These innovations address unmet medical needs and patient convenience, fostering market growth.

      KLKB1 Inhibitors Market Analysis

      KLKB1 inhibitors, including TAKHZYRO (lanadelumab), ORLADEYO (berotralstat), EKTERLY (sebetralstat), and DAWNZTERA (donidalorsen), have swiftly established themselves as standard-of-care treatments for hereditary angioedema (HAE), offering both prophylactic and acute attack management through diverse delivery routes such as oral, injectable, and RNA-based formulations.

      The recent approvals of EKTERLY as the first oral on-demand therapy and DAWNZTERA as the first RNA-based prophylactic, along with NTLA-2002 advancing into Phase III as a gene-editing therapy, underscore a shift in the pipeline toward greater treatment convenience, sustained efficacy, and the potential for curative solutions.

      Elevated plasma kallikrein levels have been associated with heightened cardiovascular risks, including myocardial infarction and stroke in men. Similarly, children with abnormal lipid profiles or metabolic syndrome exhibit higher kallikrein levels, linking the enzyme to vascular inflammation and cardiovascular disease progression.

      Thus, inhibiting plasma kallikrein (PKal) has been validated as a promising therapeutic approach for managing HAE, diabetic microvascular complications, and cardiovascular disorders. Emerging candidates such as RZ402 for diabetic macular edema (DME) represent the next wave of KLKB1 inhibitors targeting more prevalent indications, significantly broadening commercial opportunities beyond rare diseases like HAE.

      Overall, kallikrein inhibitors, while currently centered on HAE treatment, are increasingly being explored for DME, diabetic retinopathy (DR), and other vascular and inflammatory conditions.

      Learn more about the KLKB1 inhibitors @ KLKB1 Inhibitors Analysis

      KLKB1 Inhibitors Competitive Landscape

      Some of the KLKB1 inhibitors in clinical trials include Lonvoguran ziclumeran (Intellia Therapeutics), Navenibart (Astria Therapeutics), RZ402 (Rezolute), and others.

      Intellia Therapeutics' Lonvo-z, previously known as NTLA-2002, is an investigational in vivo CRISPR-based gene editing therapy designed to prevent hereditary angioedema (HAE) attacks by inactivating the KLKB1 gene, which encodes prekallikrein, the precursor to kallikrein. The therapy has earned five key regulatory designations, including Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) status from the U.S. FDA, the Innovation Passport from the UK MHRA, PRIME (Priority Medicines) designation from the EMA, and Orphan Drug Designation (ODD) from the European Commission.

      Astria Therapeutics' Navenibart is a monoclonal antibody that inhibits plasma kallikrein and is being developed for the treatment of HAE. The objective with navenibart is to deliver fast-acting and long-lasting prevention of HAE attacks through a well-established mechanism and trusted antibody modality, administered subcutaneously every 3 to 6 months. The ultimate goal is to enable people living with HAE to lead lives free from the constraints of their condition.

      The anticipated launch of these emerging therapies are poised to transform the KLKB1 inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the KLKB1 inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

      To know more about KLKB1 inhibitors clinical trials, visit @ KLKB1 Inhibitors Treatment 

      Recent Developments in the KLKB1 Inhibitors Market

      • In September 2025, Intellia Therapeutics announced it had completed enrollment in the global Phase III HAELO study of lonvoguran ziclumeran for the treatment of hereditary angioedema. Topline data are expected to be available in the first half of 2026. Intellia is on track to submit a Biologics License Application (BLA) in the second half of 2026 to support the company's plans for a US launch in the first half of 2027.
      • In September 2025, KalVista Pharmaceuticals announced that the European Commission and Swissmedic approved EKTERLY for the symptomatic treatment of acute attacks of HAE in adults and adolescents aged 12 years and older.
      • In August 2025, Ionis Pharmaceuticals announced that the FDA had approved DAWNZERA for the prophylaxis of HAE attacks in adult and pediatric patients 12 years of age and older. DAWNZERA is the first and only RNA-targeted medicine approved for the treatment of hereditary angioedema.
      • In August 2025, Astria Therapeutics announced that it had exclusively licensed development and commercialization rights in Japan to Kaken Pharmaceutical for navenibart, a Phase III development candidate for the preventive treatment of HAE.
      • In July 2025, KalVista Pharmaceuticals announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK granted marketing authorization, and the US FDA had approved EKTERLY for the treatment of HAE attacks in adults and adolescents aged 12 years and older.
      • In June 2025, Intellia Therapeutics announced three-year follow-up data from the Phase I portion of the ongoing Phase I/II study in patients with HAE after receiving a single dose of lonvo-z (NTLA-2002). Results were presented orally at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025.
      • In June 2025, Astria Therapeutics announced positive initial results from the target enrollment group in the ongoing ALPHA-SOLAR long-term open-label trial evaluating navenibart in HAE patients. These results demonstrated robust overall reduction in the monthly attack rate (92% mean and 97% median) and further supported its favorable safety and tolerability profile, and potential every three-month (Q3M) and every six-month (Q6M) dosing regimens.

      What are KLKB1 Inhibitors?

      KLKB1 inhibitors act on plasma kallikrein, a pivotal enzyme in the kallikrein–kinin system (KKS) that cleaves high-molecular-weight kininogen to produce bradykinin, a key mediator of vasodilation, vascular permeability, pain, and inflammation. Dysregulation of this pathway is linked to various inflammatory, cardiovascular, metabolic, and thrombotic conditions, positioning KLKB1 as an essential regulator of vascular function and immune activity. In addition to suppressing bradykinin generation, KLKB1 inhibition affects coagulation pathways and interacts with the complement system, suggesting a broader role in maintaining vascular balance and regulating inflammatory processes. Emerging research underscores its therapeutic potential in retinal vascular leakage, diabetic complications, and thrombosis prevention, highlighting its broader relevance beyond hereditary angioedema.

      KLKB1 Inhibitors Epidemiology Segmentation

      The KLKB1 inhibitors market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020–2034 across the leading markets. As per DelveInsight's assessment, the total diagnosed prevalent cases of HAE in the 7MM in 2024 were ~14,000, which is expected to increase by 2034, at a considerable CAGR.

      The KLKB1 inhibitor target patient pool is segmented into:

      • Total Cases of Selected Indications For KLKB1 Inhibitors
      • Total Eligible Patient Pool of Selected Indications 
      • Total Treated Cases in the Selected Indication For KLKB1 Inhibitors

      KLKB1 Inhibitors Report Metrics

      Details

      Study Period

      2020–2034

      KLKB1 Inhibitors Report Coverage

      7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

      Key Indications Covered in the Report

      Hereditary Angioedema, Diabetic Macular Edema, and others

      Key KLKB1 Inhibitor Companies

      Intellia Therapeutics, Astria Therapeutics, Rezolute, Ionis Pharmaceuticals, KalVista Pharmaceuticals, BioCryst Pharmaceuticals, Takeda Pharmaceuticals, and others

      Key KLKB1 Inhibitors

      Lonvoguran ziclumeran, Navenibart (STAR-0215), RZ402, DAWNZERA, EKTERLY, ORLADEYO, TAKHZYRO, and others

      Scope of the KLKB1 Inhibitors  Market Report

      • KLKB1 Inhibitors Therapeutic Assessment: KLKB1 Inhibitors current marketed and emerging therapies
      • KLKB1 Inhibitors Market Dynamics: Conjoint Analysis of Emerging KLKB1 Inhibitors Drugs
      • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
      • Unmet Needs, KOL's views, Analyst's views, KLKB1 Inhibitors Market Access and Reimbursement

      Discover more about KLKB1 inhibitors in development @ KLKB1 Inhibitors Clinical Trials

      Table of Contents

      1

      KLKB1 Inhibitor Market Key Insights

      2

      KLKB1 Inhibitor Market Report Introduction

      3

      Executive Summary of KLKB1 Inhibitors

      4

      Key Events

      5

      Epidemiology and Market Forecast Methodology

      6

      KLKB1 Inhibitors Market Overview at a Glance in the 7MM

      6.1

      KLKB1 Inhibitor Market Share (%) Distribution by Indication in 2024

      6.2

      KLKB1 Inhibitor Market Share (%) Distribution by Indication in 2034

      7

      KLKB1 Inhibitors: Background and Overview

      8

      Treatment and Management

      9

      Target KLKB1 Inhibitor Patient Pool

      9.1

      Key Findings

      9.2

      Assumptions and Rationale: 7MM

      9.3

      Epidemiology Scenario in the 7MM

      9.3.1

      Total Cases of Selected Indication for KLKB1 Inhibitors in the 7MM

      9.3.2

      Total Eligible Patient Pool for KLKB1 Inhibitors in Selected Indications in the 7MM

      9.3.3

      Total Treatable Cases in Selected Indications for KLKB1 Inhibitors in the 7MM

      10

      Marketed KLKB1 Inhibitor Therapies

      10.1

      Key Competitors

      10.2

      EKTERLY (sebetralstat): KalVista Pharmaceuticals

      10.2.1

      Product Description

      10.2.2

      Regulatory milestones

      10.2.3

      Other developmental activities

      10.2.4

      Clinical development

      10.2.5

      Safety and efficacy

      10.2.6

      Analyst Views

      10.3

      TAKHZYRO (lanadelumab-flyo): Takeda Pharmaceutical 

      List to be continued in the report…

      11

      Emerging KLKB1 Inhibitor Therapies

      11.1

      Key Competitors

      11.2

      Lonvoguran ziclumeran (lonvo-z): Intellia Therapeutics

      11.2.1

      Product Description

      11.2.2

      Other developmental activities

      11.2.3

      Clinical development

      11.2.4

      Safety and efficacy

      11.2.5

      Analyst Views

      11.3

      Navenibart (STAR-0215): Astria Therapeutics

      List to be continued in the report…

      12

      KLKB1 Inhibitors Market: Seven Major Market Analysis

      12.1

      Key Findings

      12.2

      KLKB1 Inhibitor Market Outlook

      12.3

      Key KLKB1 Inhibitor Market Forecast Assumptions

      12.4

      Total Market Size of KLKB1 Inhibitors in the 7MM

      12.5

      The United States KLKB1 Inhibitor Market Size

      12.5.1

      Market Size of KLKB1 Inhibitors by Indication in the United States

      12.5.2

      Market Size of KLKB1 Inhibitors by Therapies in the United States

      12.6

      EU4 and the UK KLKB1 Inhibitor Market Size

      12.7

      Japan KLKB1 Inhibitor Market Size

      13

      SWOT Analysis of KLKB1 Inhibitors 

      14

      KOL Views of KLKB1 Inhibitors 

      15

      Unmet Needs of KLKB1 Inhibitors 

      16

      Market Access and Reimbursement

      16.1

      United States

      16.2

      EU4 and the UK

      16.3

      Japan

      16.4

      Summary and Comparison of Market Access and Pricing Policy Developments in 2025

      16.5

      KLKB1 Inhibitors: Market Access and Reimbursement

      17

      Bibliography

      18

      KLKB1 Inhibitor Market Report Methodology

      Related Reports

      Hereditary Angioedema Market

      Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HAE companies, including Shire, Takeda Pharma, CSL Behring, Pharming Group, BioCryst Pharmaceuticals, Ionis Pharmaceuticals, KalVista Pharmaceuticals, among others.

      Hereditary Angioedema Clinical Trial Analysis 

      Hereditary Angioedema Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HAE companies, including BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., Intellia Therapeutics, among others.

      Diabetic Macular Edema Market

      Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DME companies, including Adverum Biotechnologies, Graybug Vision, Roche, Novartis, KalVista Pharmaceuticals, Ocuphire Pharma, Oxurion, YD Life Science, Allergan (AbbVie), Molecular Partners, Allergo Ophthalmics, Bausch Health, Kodiak Sciences, Clearside Biomedical, among others.

      Diabetic Macular Edema Clinical Trial Analysis 

      Diabetic Macular Edema Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic macular edema companies, including Mylan Pharmaceuticals, Kodiak Sciences, Celltrion, Exonate, Opthea, AsclepiX Therapeutics, Allgenesis Biotherapeutics, Ascentage Pharma, Rezolute, Ocuphire Pharma, Oxurion, MingSight Pharmaceuticals, Adverum Biotechnologies, among others.

      About DelveInsight

      DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

      Contact Us

      Shruti Thakur
      [email protected]
      +14699457679

      Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

      SOURCE DelveInsight Business Research, LLP

      Modal title

      Also from this source

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs,...

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.